Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTPS1 | P17812 | 4/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 5/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 4/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.33 |
| ▸ | FPR2 | P25090 | 3/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24721062 | 0.82 | KDM5B (0.46) | CTPS1KDM5BGSK3BDYRK1ADGAT1 | |
| SCHEMBL22758457 | 0.80 | CTPS1 (0.41) | CTPS1PIM1PIM2PIM3GSK3B | |
| SCHEMBL21392091 | 0.77 | MTOR (0.41) | CTPS1PIM1PIM2PIM3DGAT1 | |
| SCHEMBL21711155 | 0.76 | JAK2 (0.33) | PIM1PIM2PIM3 | |
| SCHEMBL24807007 | 0.73 | DGAT1 (0.45) | CTPS1DGAT1NOTUMCHEK1 | |
| SCHEMBL23600961 | 0.71 | NOTUM (0.44) | KDM5BPIM1PIM2PIM3DGAT1 | |
| SCHEMBL888893 | 0.71 | CHRNA7 (0.36) | — | |
| SCHEMBL13728633 | 0.69 | CYP2A6 (0.51) | — | |
| SCHEMBL14242977 | 0.69 | CHRNA7 (0.43) | — | |
| SCHEMBL15784442 | 0.69 | CHRNA7 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024133721-A1 | COMBINATIONS OF CTPS1 INHIBITOR WITH IAP INHIBITOR FOR USE IN THE TREATMENT OF CANCER | STEP PHARMA S.A.S. (FR) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024133730-A1 | CTPS1 INHIBITORS FOR USE IN THE TREATMENT OF CTPS2 DEFICIENT CANCER | STEP PHARMA S.A.S. (FR) | 2024-06-27 | — | — | WO | disclosed |
| WO-2023166076-A1 | COMBINATIONS OF CTPS1 AND BCL2 INHIBITORS FOR CANCER | STEP PHARMA S.A.S. (FR) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023166080-A1 | COMBINATION TREATMENTS COMPRISING A CTPS1 INHIBITOR AND A WEE1 INHIBITOR | STEP PHARMA S.A.S. (FR) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023166077-A1 | COMBINATION OF A CTPS1 INHIBITOR AND A ATR INHIBITOR IN CANCER THERAPY | STEP PHARMA S.A.S. (FR) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023166078-A1 | COMBINATION TREATMENTS COMPRISING A CTPS1 INHIBITOR AND A CHEK1 INHIBITOR | STEP PHARMA S.A.S. (FR) | 2023-09-07 | — | — | WO | disclosed |
| WO-2020245664-A1 | N-(5-(6-ETHOXYPYRAZIN-2-YL)PYRIDIN-2-YL)-4-(2-(METHYLSULFONAMIDO)PYRIMIDIN-4-YL) TETRAHYDRO-2H-PYRAN-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HUMAN CTPS1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | STEP PHARMA S.A.S. (FR) | 2020-12-10 | — | — | WO | disclosed |